Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.


Exciting advancements in the field of mantle cell lymphoma

Monday, August 7, 2017

John P. Leonard, M.D., professor of medicine, spoke to OncLive about some of the exciting advancements taking place in the field of mantle cell lymphoma (MCL).

In the MCL landscape, the BTK inhibitor ibrutinib (Imbruvica) has made a big difference for patients in improving their outcomes, Leonard explains.

Additionally, researchers are learning more about sub-classifying the MCL population, and the future is going to involve more combinations with ibrutinib. These include regimens with venetoclax (Venclexta), cell cycle inhibitors, or other novel compounds to try to minimize or treat resistance as well as extend the duration of remissions, he adds.